Some of the projects that we have completed in the past:
|
Diabetes-associated biomarkers - 5,808 assays |
|
Nested case-control study of IGFs and prostate cancer risk in EPIC | "The epidemiology and aetiology of high risk prostate cancer" - 4,260 assays |
|
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial – 10,000 assays |
|
The CALERIE and parallel mouse study sample |
|
The Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study – 10,000 assays |
|
The Prostate Cancer Prevention Trial (PCPT) – 20,000 assays |
|
Department of Defense (DOD) Prostate Cancer Research Program Development award: Distinguishing Lethal from Indolent Prostate Cancer with Free Insulin-Like Growth Factor Levels |
|
The Transdisciplinary Research on Energetics and Cancer (TREC) Study – 5,000 assays |
|
The Nurses’ Heath Study (NHS) – 73,000 assays |
|
The Health Professionals Follow-Up Study (HPFS) – 10,000 assays |
|
The Physicians’ Health Study (PHS I and II) – 31,000 assays |
|
Endogenous hormones and postmenopausal breast cancer: Etiologic insights and improving risk prediction |
|
The Cardiovascular Health Study (CHS) – 10,000 assays |
|
National Cancer Institute of Canada Clinical Trial Group - A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women (NCIC CTG MA14 study) – 1000 assays |
|
American Cancer Society Cancer Prevention Study (CPS) – 7,000 assays |
|
Laval University Breast Density Study – 5,500 assays |
|
EPIC pancreatic cancer |
|
Clues to Heart Diseases and Cancer (CLUE) – 546 assays |
|
Hawai’i Multi-Ethnic Cohort Study
|
|
Prostate Cancer Case Control Study – 1,500 assays |
|
NIH Kidney Cancer Study – 5,324 assays |